"Receptors, Estrogen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important.
| Descriptor ID |
D011960
|
| MeSH Number(s) |
D12.776.826.750.350 D12.776.930.778.350
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Estrogen".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Estrogen".
This graph shows the total number of publications written about "Receptors, Estrogen" by people in this website by year, and whether "Receptors, Estrogen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 12 | 9 | 21 |
| 1995 | 9 | 7 | 16 |
| 1996 | 4 | 6 | 10 |
| 1997 | 9 | 11 | 20 |
| 1998 | 8 | 11 | 19 |
| 1999 | 9 | 9 | 18 |
| 2000 | 17 | 11 | 28 |
| 2001 | 18 | 15 | 33 |
| 2002 | 16 | 15 | 31 |
| 2003 | 19 | 20 | 39 |
| 2004 | 17 | 20 | 37 |
| 2005 | 22 | 30 | 52 |
| 2006 | 18 | 23 | 41 |
| 2007 | 25 | 18 | 43 |
| 2008 | 12 | 19 | 31 |
| 2009 | 18 | 23 | 41 |
| 2010 | 30 | 25 | 55 |
| 2011 | 22 | 37 | 59 |
| 2012 | 26 | 38 | 64 |
| 2013 | 14 | 29 | 43 |
| 2014 | 14 | 30 | 44 |
| 2015 | 16 | 22 | 38 |
| 2016 | 10 | 16 | 26 |
| 2017 | 10 | 26 | 36 |
| 2018 | 8 | 22 | 30 |
| 2019 | 12 | 15 | 27 |
| 2020 | 8 | 19 | 27 |
| 2021 | 10 | 16 | 26 |
| 2022 | 3 | 17 | 20 |
| 2023 | 2 | 15 | 17 |
| 2024 | 5 | 9 | 14 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Estrogen" by people in Profiles.
-
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Mol Cancer Ther. 2024 Oct 01; 23(10):1494-1510.
-
The Estrogen Receptor-Related Orphan Receptors Regulate Autophagy through TFEB. Mol Pharmacol. 2024 Sep 17; 106(4):164-172.
-
Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial. Nat Med. 2024 Aug; 30(8):2242-2250.
-
Metabolic regulator ERR? governs gastric stem cell differentiation into acid-secreting parietal cells. Cell Stem Cell. 2024 Jun 06; 31(6):886-903.e8.
-
Using genome and transcriptome data from African-ancestry female participants to identify putative breast cancer susceptibility genes. Nat Commun. 2024 May 02; 15(1):3718.
-
Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive Breast Cancer. Clin Cancer Res. 2024 May 01; 30(9):1889-1905.
-
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. J Clin Oncol. 2024 Jul 01; 42(19):2281-2294.
-
Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer. J Clin Oncol. 2024 Aug 01; 42(22):2632-2636.
-
Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor-Positive Breast Cancer. JAMA Oncol. 2024 Apr 01; 10(4):508-515.
-
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2024 Mar 01; 10(3):362-371.